
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma is a promising company with a strong commercialization strategy for their CAR-T candidate, ronde-cel, and their development of LYL273 for mCRC. Their focus on competing with current CAR-T therapies and seeking accelerated approval, along with the potential efficacy and safety of their treatments, make them a favorable investment opportunity. The company's acquisition of control over their manufacturing process and investment in R&D also show dedication to their success in the competitive cell therapy market.
Bears say
Lyell Immunopharma is a cell therapy company with potential in the treatment of cancer. While the development of ronde-cel and the success of other therapies are promising, the company faces potential risks in obtaining regulatory approvals and securing funding. There is also a risk of insolvency and decreased share price if the company is unable to raise enough capital, despite strong leadership from the lead independent director. Additionally, risks related to intellectual property and clinical trials should be considered when evaluating the potential of this stock.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares